Update on the role of Interleukin 17 in rheumatologic autoimmune diseases

Cytokine

Volumn 75, Issue 2, 2015, Pages 207-215

  Konya, Christine ^a   Paz, Ziv ^a   Apostolidis, Sokratis A ^a   Tsokos, George C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Biological agents; Interleukin 17

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; IXEKIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SECUKINUMAB; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; IMMUNOLOGY; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; SPONDYLITIS, ANKYLOSING;

ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATION; INTERLEUKIN-17; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; SPONDYLITIS, ANKYLOSING;

EID: 84939777306     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.01.003     Document Type: Article

References (107)

1. Kavanaugh A., Ritchlin C., Rahman P., Puig L., Gottlieb A.B., Li S., et al. an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals Rheum Diseases 2014, 73(6):1000-1006. PubMed PMID: 24553909; PubMed Central PMCID: PMC4033146. 10.1136/annrheumdis-2013-204741.
2. Tausend W., Downing C., Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J. Cutaneous Med Surgery 2014, 18:1-14. PubMed PMID: 24518655.
3. Wofford J., Menter A. Ustekinumab for the treatment of psoriatic arthritis. Exp Rev Clinical Immunol 2014, 10(2):189-202. PubMed PMID: 24410536. 10.1586/1744666X.2014.878649.
4. Rouvier E., Luciani M.F., Mattei M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150(12):5445-5456. PubMed PMID: 8390535.
5. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155(12):5483-5486. PubMed PMID: 7499828.
6. Hymowitz S.G., Filvaroff E.H., Yin J.P., Lee J., Cai L., Risser P., et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001, 20(19):5332-5341. PubMed PMID: 11574464; PubMed Central PMCID: PMC125646. 10.1093/emboj/20.19.5332.
7. Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007, 282(18):13447-13455. PubMed PMID: 17355969. 10.1074/jbc.M700499200.
8. Chang S.H., Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007, 17(5):435-440. PubMed PMID: 17452998. 10.1038/cr.2007.35.
9. Wright J.F., Bennett F., Li B., Brooks J., Luxenberg D.P., Whitters M.J., et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 2008, 181(4):2799-2805. PubMed PMID: 18684971.
10. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheumatism 1999, 42(5):963-970. PubMed PMID: 10323452. 10.1002/1529-0131(199905)42:5<963::AID-ANR153.0.CO;2-E.
11. Lubberts E., Joosten L.A., van de Loo F.A., Schwarzenberger P., Kolls J., van den Berg W.B. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflammation Res: Official J Euro Histamine Res Soc [et al]. 2002, 51(2):102-104. PubMed PMID: 11930902.
12. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171(11):6173-6177. PubMed PMID: 14634133.
13. Aarvak T., Chabaud M., Miossec P., Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162(3):1246-1251. PubMed PMID: 9973376.
14. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6(11):1123-1132. PubMed PMID: 16200070. 10.1038/ni1254.
15. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6(11):1133-1141. PubMed PMID: 16200068; PubMed Central PMCID: PMC1618871. 10.1038/ni1261.
16. Lockhart E., Green A.M., Flynn J.L. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006, 177(7):4662-4669. PubMed PMID: 16982905.
17. Shibata K., Yamada H., Hara H., Kishihara K., Yoshikai Y. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 2007, 178(7):4466-4472. PubMed PMID: 17372004.
18. Rachitskaya A.V., Hansen A.M., Horai R., Li Z., Villasmil R., Luger D., et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008, 180(8):5167-5171. PubMed PMID: 18390697; PubMed Central PMCID: PMC2442579.
19. Roark C.L., French J.D., Taylor M.A., Bendele A.M., Born W.K., O'Brien R.L. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J Immunol 2007, 179(8):5576-5583. PubMed PMID: 17911645; PubMed Central PMCID: PMC2768546.
20. Aggarwal S., Gurney A.L. IL-17: prototype member of an emerging cytokine family. J Leukocyte Biol 2002, 71(1):1-8. PubMed PMID: 11781375.
21. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14(2):155-174. PubMed PMID: 12651226.
22. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3(6):811-821. PubMed PMID: 8777726.
23. Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K., et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007, 179(8):5462-5473. PubMed PMID: 17911633; PubMed Central PMCID: PMC2849293.
24. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30(1):108-119. PubMed PMID: 19144317. 10.1016/j.immuni.2008.11.009.
25. Shen F., Gaffen S.L. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008, 41(2):92-104. PubMed PMID: 18178098; PubMed Central PMCID: PMC2667118. 10.1016/j.cyto.2007.11.01.
26. Kramer J.M., Yi L., Shen F., Maitra A., Jiao X., Jin T., et al. Evidence for ligand-independent multimerization of the IL-17 receptor. J Immunol 2006, 176(2):711-715. PubMed PMID: 16393951; PubMed Central PMCID: PMC2973994.
27. Kramer J.M., Hanel W., Shen F., Isik N., Malone J.P., Maitra A., et al. Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor. J Immunol 2007, 179(10):6379-6383. PubMed PMID: 17982023; PubMed Central PMCID: PMC2973996.
28. Lindemann M.J., Hu Z., Benczik M., Liu K.D., Gaffen S.L. Differential regulation of the IL-17 receptor by gammac cytokines: inhibitory signaling by the phosphatidylinositol 3-kinase pathway. J Biol Chem 2008, 283(20):14100-14108. PubMed PMID: 18348982; PubMed Central PMCID: PMC2376247. 10.1074/jbc.M801357200.
29. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136(7):2348-2357. PubMed PMID: 2419430.
30. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. New England J Med 2009, 361(9):888-898. PubMed PMID: 19710487. 10.1056/NEJMra0707449.
31. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164. PubMed PMID: 7636184.
32. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6(4):345-352. PubMed PMID: 15785760. 10.1038/ni1178.
33. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126(6):1121-1133. PubMed PMID: 16990136. 10.1016/j.cell.2006.07.035.
34. Chen Z., Laurence A., O'Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Seminars Immunol 2007, 19(6):400-408. PubMed PMID: 18166487; PubMed Central PMCID: PMC2323678. 10.1016/j.smim.2007.10.015.
35. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835-839. PubMed PMID: 8521507.
36. Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol 2004, 5(1):64-73. PubMed PMID: 14691482. 10.1038/ni1022.
37. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28(1):29-39. PubMed PMID: 18164222; PubMed Central PMCID: PMC2587175. 10.1016/j.immuni.2007.11.016.
38. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007, 282(13):9358-9363. PubMed PMID: 17277312. 10.1074/jbc.C600321200.
39. Brustle A., Heink S., Huber M., Rosenplanter C., Stadelmann C., Yu P., et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007, 8(9):958-966. PubMed PMID: 17676043. 10.1038/ni1500.
40. Zhang F., Meng G., Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008, 9(11):1297-1306. PubMed PMID: 18849990. 10.1038/ni.1663.
41. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annual Rev Immunol 2006, 24:99-146. PubMed PMID: 16551245. 10.1146/annurev.immunol.24.021605.090737.
42. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441(7090):231-234. PubMed PMID: 16648837. 10.1038/nature04754.
43. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24(2):179-189. PubMed PMID: 16473830. 10.1016/j.immuni.2006.01.001.
44. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238. PubMed PMID: 16648838. 10.1038/nature04753.
45. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421(6924):744-748. PubMed PMID: 12610626. 10.1038/nature01355.
46. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198(12):1951-1957. PubMed PMID: 14662908; PubMed Central PMCID: PMC2194162. 10.1084/jem.20030896.
47. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201(2):233-240. PubMed PMID: 15657292; PubMed Central PMCID: PMC2212798. 10.1084/jem.20041257.
48. Chen Q., Yang W., Gupta S., Biswas P., Smith P., Bhagat G., et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008, 29(6):899-911. PubMed PMID:2315; PubMed Central PMCID: PMC2633410. 10.1016/j.immuni.2008.10.011.
49. Huber M., Brustle A., Reinhard K., Guralnik A., Walter G., Mahiny A., et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc National Acad Sci United States of America 2008, 105(52):20846-20851. PubMed PMID: 19088203; PubMed Central PMCID: PMC2634912. 10.1073/pnas.0809077106.
50. Biswas P.S., Bhagat G., Pernis A.B. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?. Immunol Rev 2010, 233(1):79-96. PubMed PMID: 20192994 PubMed Central PMCID: PMC2920730. 10.1111/j.0105-2896.2009.00864.x.
51. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8(9):967-974. 10.1038/ni1488.
52. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011, 12(3):247-254. 10.1038/ni.1995. PubMed PMID: 21278738; PubMed Central PMCID: PMC3182404.
53. Durant L., Watford W.T., Ramos H.L., Laurence A., Vahedi G., Wei L., et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010, 32(5):605-615. PubMed PMID: 20493732; PubMed Central PMCID: PMC3148263. 10.1016/j.immuni.2010.05.003.
54. Chen Y., Haines C.J., Gutcher I., Hochweller K., Blumenschein W.M., McClanahan T., et al. Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity 2011, 34(3):409-421. 10.1016/j.immuni.2011.02.011.
55. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheumatism 2007, 56(9):2936-2946. PubMed PMID: 17763419; PubMed Central PMCID: PMC2323677. 10.1002/art.22866.
56. Greer J.M., McCombe P.A. The role of epigenetic mechanisms and processes in autoimmune disorders. Biol: Targets Ther 2012, 6:307-327. PubMed PMID: 23055689; PubMed Central PMCID: PMC3459549. 10.2147/BTT.S24067.
57. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheumatism 1990, 33(11):1665-1673.
58. Akimzhanov A.M., Yang X.O., Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem 2007, 282(9):5969-5972. PubMed PMID: 17218320. 10.1074/jbc.C600322200.
59. Ghizzoni M., Haisma H.J., Maarsingh H., Dekker F.J. Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discovery Today 2011, 16(11-12):504-511. PubMed PMID: 21477662. 10.1016/j.drudis.2011.03.009.
60. Ye P., Garvey P.B., Zhang P., Nelson S., Bagby G., Summer W.R., et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respiratory Cell Mol Biol 2001, 25(3):335-340. PubMed PMID: 11588011. 10.1165/ajrcmb.25.3.4424.
61. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194(4):519-527. PubMed PMID: 11514607; PubMed Central PMCID: PMC2193502.
62. Maher B.M., Mulcahy M.E., Murphy A.G., Wilk M., O'Keeffe K.M., Geoghegan J.A., et al. Nlrp-3-driven interleukin 17 production by gammadeltaT cells controls infection outcomes during Staphylococcus aureus surgical site infection. Infection Immunity 2013, 81(12):4478-4489. PubMed PMID: 24082072; PubMed Central PMCID: PMC3837970. 10.1128/IAI.01026-13.
63. Murphy A.G., O'Keeffe K.M., Lalor S.J., Maher B.M., Mills K.H., McLoughlin R.M. Staphylococcus aureus infection of mice expands a population of memory gammadelta T cells that are protective against subsequent infection. J Immunol 2014, 192(8):3697-3708. PubMed PMID: 24623128; PubMed Central PMCID: PMC3979672. 10.4049/jimmunol.1303420.
64. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003, 170(4):2106-2112. PubMed PMID: 12574382.
65. Shin H.C., Benbernou N., Esnault S., Guenounou M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999, 11(4):257-266. PubMed PMID: 10328864. 10.1006/cyto.1998.0433.
66. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006, 203(7):1685-1691. PubMed PMID: 16818675; PubMed Central PMCID: PMC2118338. 10.1084/jem.20060285.
67. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9(8):556-567. PubMed PMID: 19575028; PubMed Central PMCID: PMC2821718. 10.1038/nri2586.
68. Pappu R., Ramirez-Carrozzi V., Ota N., Ouyang W., Hu Y. The IL-17 family cytokines in immunity and disease. J Clin Immunol 2010, 30(2):185-195. PubMed PMID: 20177959. 10.1007/s10875-010-9369-6.
69. Chang S.H., Park H., Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006, 281(47):35603-35607. PubMed PMID: 17035243. 10.1074/jbc.C600256200.
70. Qian Y., Liu C., Hartupee J., Altuntas C.Z., Gulen M.F., Jane-Wit D., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8(3):247-256. PubMed PMID: 17277779. 10.1038/ni1439.
71. Van Bezooijen R.L., Van Der Wee-Pals L., Papapoulos S.E., Lowik C.W. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Annals Rheumatic Diseases 2002, 61(10):870-876. PubMed PMID: 12228154; PubMed Central PMCID: PMC1753923.
72. Koenders M.I., Joosten L.A., van den Berg W.B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Annals Rheumatic Diseases 2006, 65. Suppl 3:iii29-33, PubMed PMID: 17038468; PubMed Central PMCID: PMC1798387. 10.1136/ard.2006.058529.
73. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203(12):2673-2682. PubMed PMID: 17088434; PubMed Central PMCID: PMC2118166. 10.1084/jem.20061775.
74. Adamopoulos I.E., Chao C.C., Geissler R., Laface D., Blumenschein W., Iwakura Y., et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 2010, 12(1):R29. PubMed PMID: 20167120; PubMed Central PMCID: PMC2875663. 10.1186/ar2936.
75. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167(1):141-149. PubMed PMID: 15972960; PubMed Central PMCID: PMC1603454. 10.1016/S0002-9440(10)62961-6.
76. Koenders M.I., Marijnissen R.J., Devesa I., Lubberts E., Joosten L.A., Roth J., et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheumatism 2011, 63(8):2329-2339. PubMed PMID: 21520013. 10.1002/art.30418.
77. Metawi S.A., Abbas D., Kamal M.M., Ibrahim M.K. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011, 30(9):1201-1207. PubMed PMID: 21874405. 10.1007/s10067-011-1737-y.
78. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheumatism 2004, 50(2):650-659. PubMed PMID: 14872510. 10.1002/art.20001.
79. LeGrand A., Fermor B., Fink C., Pisetsky D.S., Weinberg J.B., Vail T.P., et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheumatism 2001, 44(9):2078-2083. PubMed PMID: 11592370. 10.1002/1529-0131(200109)44:9<2078::AID-ART3583.0.CO;2-J.
80. Muhl H., Bachmann M., Pfeilschifter J. Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity. Cell Microbiol 2011, 13(3):340-348. PubMed PMID: 21199257. 10.1111/j.1462-5822.2010.01559.x.
81. Paulissen S.M., van Hamburg J.P., Davelaar N., Asmawidjaja P.S., Hazes J.M., Lubberts E. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J. Immunol 2013, 191(3):1364-1372. 10.4049/jimmunol.1300274.
82. Katz Y., Nadiv O., Rapoport M.J., Loos M. IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol 2000, 120(1):22-29. PubMed Central PMCID: PMC1905614.
83. Lee J.H., Cho M.L., Kim J.I., Moon Y.M., Oh H.J., Kim G.T., et al. Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol 2009, 36(4):684-692. PubMed PMID: 19228664. 10.3899/jrheum.080169.
84. Huang Q.Q., Pope R.M. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 2009, 11(5):357-364. PubMed PMID: 19772831; PubMed Central PMCID: PMC2913446.
85. Zhu S., Pan W., Song X., Liu Y., Shao X., Tang Y., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med 2012, 18(7):1077-1086. PubMed PMID: 22660635. 10.1038/nm.2815.
86. Lee S.Y., Kwok S.K., Son H.J., Ryu J.G., Kim E.K., Oh H.J., et al. IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther 2013, 15(1):R31. PubMed PMID: 23421940; PubMed Central PMCID: PMC3672783. 10.1186/ar4179.
87. Wong C.K., Lit L.C., Tam L.S., Li E.K., Wong P.T., Lam C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127(3):385-393. PubMed PMID: 18373953. 10.1016/j.clim.2008.01.019.
88. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009, 183(5):3160-3169. PubMed PMID: 19657089; PubMed Central PMCID: PMC2766304. 10.4049/jimmunol.0900385.
89. Kyttaris V.C., Zhang Z., Kuchroo V.K., Oukka M., Tsokos G.C. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 2010, 184(9):4605-4609. PubMed PMID: 20308633; PubMed Central PMCID: PMC2926666. 10.4049/jimmunol.0903595.
90. Crispin J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181(12):8761-8766. PubMed PMID: 19050297; PubMed Central PMCID: PMC2596652.
91. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445(7128):648-651. PubMed PMID: 17187052. 10.1038/nature05505.
92. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204(13):3183-3194. PubMed PMID: 18039949; PubMed Central PMCID: PMC2150965. 10.1084/jem.20071094.
93. Kryczek I., Bruce A.T., Gudjonsson J.E., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181(7):4733-4741. PubMed PMID: 18802076; PubMed Central PMCID: PMC2677162.
94. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128(5):1207-1211. 10.1038/sj.jid.5701213.
95. Pene J., Chevalier S., Preisser L., Venereau E., Guilleux M.H., Ghannam S., et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008, 180(11):7423-7430.
96. Appel H., Maier R., Wu P., Scheer R., Hempfing A., Kayser R., et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13(3):R95. PubMed PMID: 21689402; PubMed Central PMCID: PMC3218910. 10.1186/ar3370.
97. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371(9625):1665-1674. PubMed PMID: 18486739. 10.1016/S0140-6736(08)60725-4.
98. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371(9625):1675-1684. PubMed PMID: 18486740. 10.1016/S0140-6736(08)60726-6.
99. McInnes I.B., Kavanaugh A., Gottlieb A.B., Puig L., Rahman P., Ritchlin C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382(9894):780-789. PubMed PMID: 23769296. 10.1016/S0140-6736(13)60594-2.
100. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals Rheumatic Diseases 2014, 73(6):990-999. PubMed PMID: 24482301; PubMed Central PMCID: PMC4033144. 10.1136/annrheumdis-2013-204655.
101. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2(52):52ra72. PubMed PMID: 20926833. 10.1126/scitranslmed.3001107.
102. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Brit J Dermatol 2013, 168(2):412-421. PubMed PMID: 23106107. 10.1111/bjd.12110.
103. Rich P., Sigurgeirsson B., Thaci D., Ortonne J.P., Paul C., Schopf R.E., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Brit J Dermatol 2013, 168(2):402-411. PubMed PMID: 23362969. 10.1111/bjd.12112.
104. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Aelion J.A., et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014, 41(3):414-421. PubMed PMID: 24429175. 10.3899/jrheum.130637.
105. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Annals Rheumatic Diseases 2013, 72(6):863-869. PubMed PMID: 22730366. 10.1136/annrheumdis-2012-201601.
106. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New England J Med 2012, 366(13):1190-1199. PubMed PMID: 22455413. 10.1056/NEJMoa1109997.
107. Genovese M.C., Greenwald M., Cho C.S., Berman A., Jin L., Cameron G.S., et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014, 66(7):1693-1704. PubMed PMID: 24623718. 10.1002/art.38617.